Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Autor:
Yasuo Ohkura, Tomokazu Kishiki, Tadahiko Masaki, Takashi Watanabe, Jyunji Furuse, Kouki Ohtsuka, Hiroaki Ohnishi, Masanori Sugiyama
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are acti